DVT (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (high certainty).
1 finding from 1 review
Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin showed no clear difference in symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic DVT · participants at risk of venous thromboembolism
1 finding from 1 review
Asymptomatic DVT · participants at risk of venous thromboembolism
1 finding from 1 review
Symptomatic recurrent DVT at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent DVT at 3 months compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
Symptomatic recurrent DVT at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent DVT at 3 months compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
DVT (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity
It is very uncertain whether unfractionated heparin changes DVT (symptomatic, asymptomatic, non‐fatal) (5 to 8 days after surgery) compared with low molecular weight heparin (very low certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin leads to lower symptomatic DVT compared with no thromboprophylaxis (high certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
Ultra‐low‐molecular‐weight heparin leads to lower symptomatic DVT compared with placebo (high certainty).
1 finding from 1 review
Symptomatic DVT · participants at risk of venous thromboembolism
1 finding from 1 review
Asymptomatic DVT · adults undergoing KA
It is very uncertain whether low‐molecular‐weight heparin changes asymptomatic DVT: compared with no prophylaxis (very low certainty).
1 finding from 1 review
Asymptomatic DVT · participants at risk of venous thromboembolism
1 finding from 1 review
Symptomatic DVT · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic DVT ( compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic DVT · adults undergoing KA
Low‐molecular‐weight heparin showed no clear difference in symptomatic DVT: assessed by presence of symptoms and confirmed by a… compared with no prophylaxis (low certainty).
1 finding from 1 review
Symptomatic DVT · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
1 finding from 1 review
Symptomatic DVT · participants at risk of venous thromboembolism
NMES showed no clear difference in symptomatic DVT compared with low‐dose heparin (low certainty).
1 finding from 1 review
Asymptomatic DVT · participants at risk of venous thromboembolism
NMES showed no clear difference in asymptomatic DVT compared with low‐dose heparin (low certainty).
1 finding from 1 review